J Stroke.  2024 May;26(2):342-346. 10.5853/jos.2023.04056.

Sodium-Glucose Cotransporter 2 Inhibitor Improves Neurological Outcomes in Diabetic Patients With Acute Ischemic Stroke

• Yang W
• Kim JM
• Chung M
• Ha J
• Kang DW
• Lee EJ
• Jeong HY
• Jung KH
• Sung H
• Paeng JC
• Lee SH

• KMID: 2556057
• DOI: http://doi.org/10.5853/jos.2023.04056

Figure

• 

  Figure 1. Impact of SGLT2i on the metabolism of various organs. (A) Representative 18F-fluorodeoxyglucose positron emission tomography images of nondiabetic controls, diabetic patients without SGLT2i use, and diabetic patients with SGLT2i use, measured in supraclavicular brown and SAT. The measurement sites are indicated by arrows and dotted circles. Comparison of (B) brown and (C) SAT 18F-fluorodeoxyglucose uptake among nondiabetic controls, diabetic patients without SGLT2i use, and diabetic patients with SGLT2i use. *P<0.05; **P<0.01. BAT, brown adipose tissue; DM, diabetes mellitus; SAT, subcutaneous adipose tissue; SGLT2i, sodium-glucose cotransporter 2 inhibitor; NS, no significant difference.

Reference

References

1. Takashima M, Nakamura K, Kiyohara T, Wakisaka Y, Hidaka M, Takaki H, et al. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun Biol. 2022; 5:653.

2. Abdel-Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch Pharm Res. 2020; 43:514–525.

3. Guo M, Ding J, Li J, Wang J, Zhang T, Liu C, et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20:1977–1982.

4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.

5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357.

6. Millar P, Pathak N, Parthsarathy V, Bjourson AJ, O’Kane M, Pathak V, et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017; 234:255–267.

7. Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Alzheimers Res Ther. 2020; 12:40.

8. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014; 10:24–36.

9. Takx RA, Ishai A, Truong QA, MacNabb MH, Scherrer-Crosbie M, Tawakol A. Supraclavicular brown adipose tissue 18F-FDG uptake and cardiovascular disease. J Nucl Med. 2016; 57:1221–1225.